Introduction
============

Liver fibrosis is a reversible wound-healing response in the liver to cellular injury, reflecting the balance between liver repair and scar tissue formation. Liver fibrogenesis is driven by transdifferentation of hepatic stellate cells (HSCs) to α-smooth muscle actin (SMA)-positive myofibroblasts, which represents excessive accumulation of extracellular matrix (ECM) ([@B24]; [@B59]). It is generally believed that HSCs activation is the main cell event during the progression of liver fibrosis ([@B7]). Liver fibrosis usually occurs in response to chronic inflammation caused by viral infection, toxic substances, alcohol abuse, cholestasis, and fatty deposition of the liver ([@B29]). So far, there is no specific drug to reverse the process of liver fibrosis. Therefore, it is important to elucidate the pathogenesis of hepatic fibrosis for the prevention and treatment.

It has been found that hepatic endoplasmic reticulum (ER) stress plays an important role in many liver diseases and becomes a new target for drug discovery ([@B49]). The ER is responsible for such tasks as protein synthesis, folding, assembly and shipping in eukaryotic cells ([@B28]). Homeostatic regulation of the ER is under the control of three evolutionary conserved pathways: inositol-requiring enzyme 1 alpha (IRE1α), double-stranded RNA-activated kinase (PKR)-like ER kinase (PERK) and activating transcription factor 6 (ATF6) ([@B39]; [@B30]). IRE1α as an executor of cell fate determination under ER stress, it also affects the fate of ATF6 and PERK signaling pathways ([@B35]; [@B8]). The study found that IRE1α signaling pathway was first activated after giving the mice a single carbon tetrachloride (CCl~4~) stimulus, ([@B35]; [@B19]) and one of our previous study found that IRE1α signaling was first activated in CCl~4~-induced liver fibrosis ([@B55]). The activated IRE1α has dual activities of protein kinase and RNase, which its oligomerization-mediated trans-autophosphorylation in turn leads to IRE1α RNase activation ([@B14]). In recent years, some studies have shown that IRE1α RNase activation governs cell fate through selectively cleaving mRNA and microRNAs (miRNAs) ([@B16]; [@B54]; [@B43]). STF-083010 is identified as a new chemical molecule that selectively inhibits IRE1α RNase activity and degradation of specific mRNA without affecting its kinase activity. Moreover, it has shown a potential to effectively control ER stress-induced disorders ([@B47]; [@B37]). Thus, it is interesting to explore the effect of IRE1α RNase specific inhibitor STF-083010 on hepatic fibrosis.

This study aimed to explore the effect of STF-083010 on CCl~4~-induced liver injury and subsequent liver fibrosis in mice. Our results found that IRE1α RNase specific inhibitor STF-083010 protected against CCl~4~-induced hepatocyte death. The present study provided partial evidence that hepatic IRE1α RNase was involved in CCl~4~-induced liver fibrosis through regulating hepatic miR-122. The research results will provide a theoretical basis for discovering new effective therapeutic targets and reversing hepatic fibrosis.

Materials and Methods {#s1}
=====================

Chemicals and Reagents
----------------------

CCl~4~, fast green FCF, direct red 80 (sirius red) and anti-α-SMA monoclonal antibody were purchased from Sigma Chemical Co. (St. Louis, MO, United States). STF-083010 was from MedChemexpress (New Jersey, United States). Anti-p-IRE1α/IRE1α antibodies, anti-(glucose-regulated protein, GRP78) antibody, TRIzol^®^reagent, Chemiluminescence (ECL) were from Thermo Fisher Scientific Inc (Rockford, IL, United States), anti-α-tubulin antibody and anti-3-nitrotyrosine (3-NT) antibody were from Santa Cruz Biotechnologies (Santa Cruz, CA, United States). RNase-free DNase and AMV were purchased from Promega Corporation (Madison, WI, United States). LightCycler480^®^SYBR Green I Master was from Roche Diagnostics GmbH (Mannheim, Germany). All primers were synthesized by Invitrogen Trading (Shanghai) Co., Ltd. All other reagents were purchased from Sigma Chemical Co. (St. Louis, MO, United States) if not otherwise stated.

Animals and Treatments
----------------------

Male ICR mice (6--8w, 24--26 g) were from Beijing Vital River (China). The animal experimental procedures were reviewed and approved by the Animal Ethical Committee of Anhui Medical University (Permit Number: LLSC20140047). The mice were allowed free access to water and food and were maintained on a suitable environment \[temperature (20--25°C) and humidity (50 ± 5%)\] for a period of 1 week before use. Mice were randomly divided into four groups. In CCl~4~ alone, mice were intraperitoneally (i.p.) injected with CCl~4~ (0.15 ml/kg, 10% soluble in corn oil, twice a week) for 8 weeks. In control group, mice were normal feeding with the dissolvent injection. In STF-083010+CCl~4~ group, mice were injected with STF-083010 (30 mg/kg, i.p.), twice a week, beginning from the 6th week after CCl~4~ injection. In STF-083010 alone group, mice were only i.p. injected with STF-083010. All mice were sacrificed after 8 weeks with CCl~4~ treatment, blood and livers were collected for the experiment. Serum was isolated for measurement of biochemical parameters. Some liver tissues were fixed in 4% paraformaldehyde solution for histological examination and immunohistochemistry, and others were frozen immediately in lipid nitrogen for real-time RT-PCR and Western blot.

Biochemical Assays
------------------

The serum levels of alanine aminotransferase (ALT), direct bilirubin (DBIL), and total bilirubin (TBIL) were detected by automatic biochemical analyzer. Total bile acid (TBA) in serum and malondialdehyde (MDA) in tissue (refer to Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}) were measured by commercially available assay kits under manufacturer's instructions.

Histology
---------

The isolated liver tissue was fixed in freshly prepared paraformaldehyde solution (4%) for 24 h and then embedded in paraffin under standard procedures. The tissue stored in the slide was cut into 5 μm thick, and then stained with hematoxylin and eosin (H&E) for further analysis. The inflammatory cells were counted in 12 randomly selected fields from each slide (magnification × 400). The areas of hepatic necrosis were measured as the average of all necrotic fields within each slide.

Determination of Liver Fibrosis
-------------------------------

Hepatic fibrosis was determined with masson's trichrome staining and sirius red staining. Briefly, sections were deparaffinized with xylene and hydrated with gradient ethanol. In masson's trichrome staining, hepatic tissue sections were stained with Mayer hematoxylin for 3 min, magenta stained for 10 min and aniline blue stained for 5 min, and then processed to neutral gum seal. In sirius red staining, hepatic tissue sections were immersed in saturated picric acid solution (containing 0.1% Fast Green FCF and 0.1% Direct Red 80) for 2 h in the dark. A light microscope equipped with CCD digital camera (DP-80, Olympus) captures the morphology of collagen fibers. Morphometric analysis for liver fibrosis quantification was measured using whole tissue low-power images every mouse (magnification ×100). Percentages of collagen accumulation areas were measured by using NIH Image J software^[1](#fn01){ref-type="fn"}^.

Hepatic Hydroxyproline Examination
----------------------------------

Hepatic hydroxyproline (Hyp) content was measured using commercially assay kits under manufacturer's instructions ([@B48]).

Isolation of Total RNA and Real-Time RT-PCR
-------------------------------------------

Hepatic total RNA was extracted using TRIzol. The purity of total RNA was evaluated based on the absorbance ratio at 260 and 280 nm. RNase-free DNase-treated total RNA was reverse-transcribed with AMV in Biometra T Gradient Thermocycler. Real-time RT-PCR was carried out with a LightCycler^®^480 SYBR Green I kit by using gene-specific primers as listed in Table [1](#T1){ref-type="table"}. The amplification reactions were performed on a LightCycler^®^480 Instrument (Roche Diagnostics GmbH, Mannheim, Germany) with a pre-incubation step (95°C for 10 min) and 45 cycles of a three-step PCR (95°C for 15 s, 60°C for 15 s, 72°C for 20 s). The comparative C~T~-method was used to determine the amount of target genes ([@B20]; [@B11]), normalized to an endogenous reference and relative to a calibrator (2^-ΔΔCt^) using the LightCycler 480 software (Roche, version 1.5.0). All RT-PCR experiments were carried out in triplicate.

###### 

Oligonucleotide sequence of primers for real-time RT-PCR.

  Genes    Forward primers (5′--3′)         Reverse primers (5′--3′)
  -------- -------------------------------- --------------------------------
  18S      GTA ACC CGT TGA ACC CCA TT       CCA TCC AAT CGG TAG TAG CG
  TGF-β1   CGG GAA GCA GTG CCC GAA CC       GGG GGT CAG CAG CCG GTT AC
  IL-1β    GCC TCG TGC TGT CGG ACC CAT AT   TCC TTT GAG GCC CAA GGC CAC A
  MCP1     GGC TGG AGA GCT ACA AGA GG       GGT CAG CAC AGA CCT CTC TC
  IL-6     AGACAAAGCCAGAGTCCTTCAGAGA        GCC ACT CCT TCT GTG ACT CCA GC
  α-SMA    GAG ACT CTC TTC CAG CCA TCT T    TGA TCT CCT TCT GCA TCC TGT C
  XBP1s    CTG AGT CCG AAT CAG GTG CAG      GTC CAT GGG AAG ATG TTC TGG
  XBP1t    TGG CCG GGT CTG CTG AGT CCG      GTC CAT GGG AAG ATG TTC TGG
  Col1α1   CAA TGG CAC GGC TGT GTG CG       AGC ACT CGC CCT CCC GTC TT
  Col1α2   CTC ATA CAG CCG CGC CCA GG       AGC AGG CGC ATG AAG GCG AG
  Mmp9     CGG CAC GCC TTG GTG TAG CA       AGG CAG AGT AGG AGC GGC CC
  P4HA1    CCA CAG CAG AGG AAT TAC AG       ACA CTA GCT CCA ACT TCA GG
  CTGF     ACC CAA CTA TGA TTA GAG CC       TTG CCC TTC TTA ATG TTC TC

Stem-Loop RT-PCR for MiR-122
----------------------------

For detection of miR-122, total RNA was reverse-transcribed using stem-loop primer (RT miR-122: 5′- GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACC AAA C-3′; RT U6: 5′-AAC GCT TCA CGA ATT TGC GT-3′). Specific oligonucleotide primers were used for miR-122 and U6 genes: miR-122 F: 5′-TGG AGT GTG ACA ATG GTG TT-3′ and R: 5′-CCA GTG CAG GGT CCG AGG T-3′; U6: F: 5′-CTC GCT TCG GCA GCA CA-3′, and R: 5′-AAC GCT TCA CGA ATT TGC GT-3′ ([@B23]). RT reaction was carried out in Biometra T Gradient Thermocycler (16°C for 30 min, 42°C for 30 min, 85°C for 5 min and taken out the sample at 4°C). The amplification reactions were carried out and the expression levels of miR-122 were quantified as described above. MiR-122 was normalized with U6 snRNA.

Immunoblots
-----------

Hepatic lysate was prepared using homogenizing 50-80 mg liver tissue in lysis buffer supplemented with a cocktail of protease inhibitors. The concentration of protein was determined by the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL, United States). For immunoblot, same amount of protein boiled with 2× Laemmli denaturing and loading buffer was separated electrophoretically by SDS-PAGE and transferred to a polyvinylidene fluoride membrane. The membranes were incubated for 2 h with following antibodies: α-SMA (1:5000), p-IRE1α (1:2000) or IRE1α (1:2000) and GRP78 (1:2000). Alpha-tubulin was used as a loading control. The membranes were incubated with either goat anti-mouse or goat anti-rabbit IgG antibodies for 2 h. The membranes were imaged by signal development using an ECL detection kit.

Immunohistochemistry
--------------------

Liver tissue sections were deparaffinized and subsequently hydrated in gradient ethanol. After quenching endogenous peroxidase, tissue sections were incubated with anti-α-SMA monoclonal antibody (1:1000) or anti-3-nitrotyrosine (3-NT) antibody (1:200) at 4°C overnight. The color reaction was developed with Horseradish Peroxidase (HRP)-linked polymer detection system and counterstaining with hematoxylin. Alpha-SMA positive area was analyzed in each slide (magnification ×100). The percentages of α-SMA positive area were quantified using NIH Image J software in six mice from each group.

Statistical Analysis
--------------------

All data were expressed as means ± SEM. ANOVA and the Student-Newmann-Keuls *post hoc* test were used to determine differences among different groups. A *P*-value of 0.05 was set as the threshold for statistical significance.

Results
=======

STF-083010 Attenuates CCl~4~-Induced Hepatic IRE1α RNase Activation in Mice
---------------------------------------------------------------------------

The roles of IRE1α RNase activation in CCl~4~-induced liver fibrosis in mice were shown in Figure [1](#F1){ref-type="fig"}. As expected, the phosphorylation level of hepatic IRE1α was apparently activated in CCl~4~-treated mice, but STF-083010 unaffected its level in CCl~4~-treated fibrotic mice (Figure [1A](#F1){ref-type="fig"}). Further study indicated that ratios of spliced XBP1 (XBP1s) to total XBP1 (XBP1t) transcripts, an indicator of IRE1α RNase activity, were obviously elevated in CCl~4~-induced liver fibrosis in mice. Interestingly, STF-083010 markedly mitigated CCl~4~-induced upregulation of hepatic XBP1s/XBP1t (Figure [1B](#F1){ref-type="fig"}). Additionally, we found that STF-083010 had no effect on ER stress marker protein GRP78, which further demonstrated that STF-083010 was a targeted inhibitor of IRE1α RNase activity (Figure [1C](#F1){ref-type="fig"}). The results demonstrated that STF-083010 can selectively inhibit CCl~4~-induced hepatic IRE1α RNase activation in the study.

![The effect of STF-083010 (STF) on IRE1α RNase activation in CCl~4~-induced liver fibrosis in mice. Mice were i.p. injected with CCl~4~ (0.15 ml/kg, twice per week). In STF-083010+CCl~4~ group, mice were injected with STF-083010 (30 mg/kg, i.p.), twice per week, beginning from the 6th week after CCl~4~ injection. All mice were sacrificed after 8 weeks with CCl~4~ treatment. **(A,C)** Hepatic p-IRE1α, IRE1α and GRP78 were measured using immunoblot. A representative protein band for p-IRE1α or GRP78 (upper panel) and IRE1α or α-tubulin (lower panel) was shown. All experiments were repeated for four times. Quantitative analyses of scanning densitometry for p-IRE1α/IRE1α and GRP78/α-tubulin on six samples from six different mice were carried out. **(B)** Hepatic XBP1s and XBP1t mRNAs were detected using real-time RT-PCR, XBP1s/XBP1t were analyzed. All data were expressed as means ± SEM (*n* = 6). ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 versus control group. ^†^*P* \< 0.05 versus CCl~4~ group.](fphar-09-01344-g001){#F1}

STF-083010 Mitigates Liver Injury and Inflammation in CCl~4~-Treated Mice
-------------------------------------------------------------------------

As shown in Table [2](#T2){ref-type="table"}, long-term CCl~4~ treatment caused a significant increase in liver weight, however, STF-083010 had no effect on liver weight in mice. This study then analyzed the effect of STF-083010 on serum biological parameters. Certainly, CCl~4~ treatment markedly enhanced the levels of serum ALT, TBIL, DBIL, and TBA, and STF-083010 had obviously extenuated CCl~4~-induced exaltation of ALT, DBIL, and TBA levels (Table [2](#T2){ref-type="table"}). The effects of STF-083010 on hepatic histopathological damage were presented in Figure [2](#F2){ref-type="fig"}. Indeed, a large amount of inflammatory cells infiltration around necrotic tissue were observed in CCl~4~-treated liver tissue sections. Interestingly, STF-083010 manifestly mitigated CCl~4~-induced hepatic necrosis and inflammation (Figures [2C](#F2){ref-type="fig"}--[F](#F2){ref-type="fig"}). Moreover, this study also analyzed the effect of STF-083010 on CCl~4~-induced inflammatory cytokines expression. Certainly, CCl~4~ administration obviously improved the levels of hepatic transforming growth factor beta (TGF-β1), monocyte chemotactic protein 1 (MCP1), interleukin-1 (IL-1β) and IL-6 mRNAs. Of interest, STF-083010 apparently attenuated CCl~4~-induced upregulation of hepatic TGF-β1, MCP1, IL-1β, and IL-6 mRNAs (Figure [3](#F3){ref-type="fig"}). The results illustrated that STF-083010 obviously extenuated liver injury and inflammation.

###### 

Physiologic and serum parameters.

  Parameters                       Control (*n* = 11)   STF-083010 (*n* = 11)   CCl~4~ (*n* = 11)    STF-083010+CCl~4~ (*n* = 10)
  -------------------------------- -------------------- ----------------------- -------------------- ------------------------------
  Liver weight (g)                 1.72 ± 0.26          1.82 ± 0.08             2.56 ± 0.11^∗∗^      2.59 ± 0.03
  Liver to body Weight ratio (%)   4.54 ± 0.11          4.71 ± 0.10             6.41 ± 0.20^∗∗^      6.47 ± 0.10
  ALT (U/L)                        37.83 ± 4.92         45.00 ± 2.58            313.45 ± 22.76^∗∗^   237.14 ± 22.51^†^
  TBIL (μmol/l)                    3.83 ± 0.14          4.12 ± 0.55             7.87 ± 0.61^∗∗^      7.84 ± 0.63
  DBIL (μmol/l)                    0.67 ± 0.04          0.70 ± 0.18             1.42 ± 0.15^∗∗^      0.77 ± 0.20^†^
  TBA (μmol/l)                     4.01 ± 1.88          3.16 ± 1.22             13.51 ± 1.65^∗∗^     5.02 ± 1.20^††^

∗∗

P \< 0.01 versus control group;

†

P \< 0.05,

††

P \< 0.01 versus CCl

4

group. Measurement data were expressed as means ± SEM. ALT, alanine aminotransferase; TBIL, total bilirubin; DBIL, direct bilirubin; TBA, total bile acids.

![Effects of STF-083010 (STF) on liver injury and inflammation following long-term CCl~4~ treatment. Mice were i.p. injected with CCl~4~ (0.15 ml/kg, twice per week). In STF-083010+CCl~4~ group, mice were injected with STF-083010 (30 mg/kg, i.p.), twice per week, beginning from the 6th week after CCl~4~ injection. All mice were sacrificed after 8 weeks with CCl~4~ treatment. Representative hepatic histological photomicrographs in mice of control group **(A)**, STF group **(B)**, CCl~4~ group **(C)**, and combination of STF plus CCl~4~ group **(D)** are shown in the picture (H&E, magnification ×100). Scale bars are 100 μm. The number of inflammatory cells **(E)** was counted in 12 randomly selected fields from each slide. **(F)** Morphometric analysis was performed to evaluate the percentage of necrotic site in each section. All data were expressed as means ± SEM (*n* = 6). ^∗∗^*P* \< 0.01 versus control group. ^†^*P* \< 0.05 versus CCl~4~ group.](fphar-09-01344-g002){#F2}

![Effects of STF-083010 (STF) on hepatic inflammatory cytokines following long-term CCl~4~ administration. Mice were i.p. injected with CCl~4~ (0.15 ml/kg, twice per week). In STF-083010+CCl~4~ group, mice were injected with STF-083010 (30 mg/kg, i.p.), twice per week, beginning from the 6th week after CCl~4~ injection. All mice were sacrificed after 8 weeks with CCl~4~ treatment. Hepatic TGF-β1 **(A)**, MCP1 **(B)**, IL-1β **(C)**, and IL-6 **(D)** mRNAs were measured using real-time RT-PCR. All data were expressed as means ± SEM (*n* = 6). ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 versus control group. ^†^*P* \< 0.05, ^††^*P* \< 0.01 versus CCl~4~ group.](fphar-09-01344-g003){#F3}

STF-083010 Reduces the Expression of Hepatic α-SMA in CCl~4~-Treated Mice
-------------------------------------------------------------------------

The effect of STF-083010 on hepatic α-SMA, a marker related to HSCs activation, was analyzed. Immunohistochemistry results showed that the majority of hepatic α-SMA was distributed in the bridging fibrosis area (Figure [4C](#F4){ref-type="fig"}), but hepatic α-SMA was almost no distributed in control group (Figure [4A](#F4){ref-type="fig"}) and STF-083010 alone group (Figure [4B](#F4){ref-type="fig"}). Further analysis illustrated that the percentages of hepatic α-SMA positive area in CCl~4~-treated mice were obviously enhanced (Figure [4E](#F4){ref-type="fig"}). Western blot showed that CCl~4~-induced hepatic α-SMA protein was evidently upregulated in mice (Figure [4F](#F4){ref-type="fig"}). Interestingly, STF-083010 evidently attenuated the elevation of hepatic α-SMA protein during the CCl~4~-induced liver fibrosis (Figures [4D](#F4){ref-type="fig"}--[F](#F4){ref-type="fig"}). Correspondingly, long-term CCl~4~ treatment obviously raised the expression of hepatic α-SMA mRNA. Of interest, STF-083010 markedly inhibited CCl~4~-induced up-regulation of hepatic α-SMA mRNA (Figure [4G](#F4){ref-type="fig"}).

![Effects of STF-083010 (STF) on CCl~4~-induced expression of hepatic α-SMA. Mice were i.p. injected with CCl~4~ (0.15 ml/kg, twice per week). In STF-083010+CCl~4~ group, mice were injected with STF-083010 (30 mg/kg, i.p.), twice per week, beginning from the 6th week after CCl~4~ injection. All mice were sacrificed after 8 weeks with CCl~4~ treatment. Representative liver tissue sections stained with immunohistochemistry for α-SMA (**A**, control; **B,** STF; **C**, CCl~4~; and **D**, STF+CCl~4~, magnification × 100). Scale bars are 100 μm. **(E)** Morphometrical analysis was implemented for assessing percentages of a-SMA positive area in each section. **(F)** Hepatic α-SMA protein was measured using immunoblot. Quantitative analyses of scanning densitometry for α-SMA on six samples from six different mice were carried out. **(G)** Hepatic α-SMA mRNA was measured using real-time RT-PCR. All data were expressed as means ± SEM (*n* = 6). ^∗∗^*P* \< 0.01 versus control group. ^†^*P* \< 0.05, ^††^*P* \< 0.01 versus CCl~4~ group.](fphar-09-01344-g004){#F4}

STF-083010 Extenuates CCl~4~-Induced Liver Injury and Subsequent Liver Fibrosis
-------------------------------------------------------------------------------

Liver fibrosis was determined using masson's trichrome staining and sirius red staining. Indeed, obvious bridging fibers were observed in the liver of CCl~4~-treated mice (Figures [5C,G](#F5){ref-type="fig"}), but almost no observed in control group (Figures [5A,E](#F5){ref-type="fig"}) and STF-083010 alone group (Figures [5B,F](#F5){ref-type="fig"}). STF-083010 evidently extenuated liver injury and subsequent liver fibrosis in mice (Figures [5D,H](#F5){ref-type="fig"}). Morphological analysis demonstrated that fibrotic area was markedly decreased in mice treated with STF-083010 plus CCl~4~ versus CCl~4~ alone (Figure [5I](#F5){ref-type="fig"}). The effect of STF-083010 on hepatic hydroxyproline (Hyp), an indicator of liver fibrosis, was analyzed. CCl~4~-induced hepatic Hyp content was markedly enhanced in mice, and STF-083010 reduced CCl~4~-induced exaltation of hepatic Hyp content (Figure [5J](#F5){ref-type="fig"}).

![Effects of STF-083010 (STF) on CCl~4~-induced liver injury and liver fibrosis. Mice were i.p. injected with CCl~4~ (0.15 ml/kg, twice per week). In STF-083010+CCl~4~ group, mice were injected with STF-083010 (30 mg/kg, i.p.), twice per week, beginning from the 6th week after CCl~4~ injection. All mice were sacrificed after 8 weeks with CCl~4~ treatment. **(A--H)** Representative liver tissue sections stained with masson's trichrome and sirius red for collagen. A/E (control), B/F (STF), C/G (CCl~4~), and D/H (combination of STF plus CCl~4~) are shown (magnification × 100). Scale bars are 100 μm. **(I)** Morphometric analysis was performed to evaluate the percentage of specific collagen fibers in each section. **(J)** Hepatic hydroxyproline was measured. All data were expressed as means ± SEM (*n* = 6). ^∗∗^*P* \< 0.01 versus control group. ^††^*P* \< 0.01 versus CCl~4~ group.](fphar-09-01344-g005){#F5}

Effects of STF-083010 on CCl~4~-Induced Expression of Hepatic MiR-122 and Its Target Genes
------------------------------------------------------------------------------------------

To further study the effect of STF-083010 on miR-122 in liver fibrosis, this study examined the effect of STF-083010 on the expression level of hepatic miR-122 using real-time RT-PCR. The repeated CCl~4~ administration led to evident downregulation of hepatic miR-122 in mice Figure [6A](#F6){ref-type="fig"}). Conversely, the CCl~4~-induced hepatic miR-122 could be significantly raised by STF-083010. Indeed, the downstream target genes of miR-122, such as synthesis of collagen (Col1α1, Col1α2, and P4HA1), matrix metallopeptidase (Mmp9), connective tissue growth factor (CTGF) (Figures [6B](#F6){ref-type="fig"}--[F](#F6){ref-type="fig"}) and inflammatory factors (TGF-β1, MCP1, and IL-1β) (Figure [3](#F3){ref-type="fig"}) mRNAs levels, were upregulated in CCl~4~-induced fibrotic mice. Interestingly, this study also found that STF-083010 obviously elevated the level of miR-122 expression and decreased its target genes related with collagen maturation and ECM production.

![Effects of STF-083010 (STF) treatment on CCl~4~-induced expression of hepatic miR-122 and its target genes. Mice were i.p. injected with CCl~4~ (0.15 ml/kg, twice per week). In STF-083010+CCl~4~ group, mice were injected with STF-083010 (30 mg/kg, i.p.), twice per week, beginning from the 6th week after CCl~4~ injection. All mice were sacrificed after 8 weeks with CCl~4~ treatment. Hepatic miR-122 and its target genes related with collagen maturation and ECM production, such as Col1α1, Col1α2, P4HA1, Mmp9, and CTGF mRNAs were measured using real-time RT-PCR. **(A)** miR-122; **(B)** Col1α1; **(C)** Col1α2; **(D)** P4HA1; **(E)** Mmp9; **(F)** CTGF. All data were expressed as means ± SEM (*n* = 6). ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 versus control group. ^†^*P* \< 0.05, ^††^*P* \< 0.01 versus CCl~4~ group.](fphar-09-01344-g006){#F6}

Discussion
==========

Under conditions of ER stress, IRE1α RNase is activated through dimerization and autophosphorylation and removes 26 nucleotides from unspliced X-box binding protein 1 (XBP1u) mRNA to generate XBP1s, producing a functional XBP1s transcription factor ([@B8]). A few studies recently reported that IRE1α RNase activation was involved in fibrosis by splicing XBP1 mRNA ([@B41]; [@B18]). However, it remains unclear whether the mechanism of independent IRE1α RNase cleaving XBP1 mRNA is involved in liver injury and liver fibrosis. Additionally, a recent study showed that STF-083010 could efficiently correct nonalcoholic fatty liver disease (NAFLD) by limiting IRE1α signaling ([@B31]). Repeated CCl~4~ stimulation can lead to persistent liver injury and subsequent liver fibrosis. In this study, the effect and possible mechanism of IRE1α RNase inhibitor STF-083010 on CCl~4~-induced liver injury and subsequent liver fibrosis were explored in mice. As expected, pharmacological inhibition of the chemical small molecule STF-083010 on IRE1α RNase activity markedly extenuated CCl~4~-induced liver injury and thus protected against liver fibrosis in mice.

It was generally believed that the main cell event in the progression of liver fibrosis was the activation of HSCs ([@B7]). In fact, the studies showed that α-SMA was a marker of the initiation stage of HSCs activation, which was evidently raised in the liver region of bridging fibrosis, and the mRNA levels of hepatic col1α1 and col1α2, markers for the perpetuation stage of HSCs activation, were clearly elevated in fibrotic mice ([@B46]; [@B55]; [@B18]). Several reports demonstrated that inflammatory cytokines such as MCP1, IL-1β, IL-6, and TGF-β1 were closely related to the activation of HSCs ([@B42]; [@B56]; [@B26]; [@B25]). It was reported that pre-treatment with IRE1α inhibitor reduced pro-inflammatory cytokines production in tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS) dermal fibroblasts (DFs) ([@B15]). On the other hand, these inflammatory cytokines were also the downstream target genes of miR-122 ([@B21]; [@B45]; [@B58]; [@B51]). In the present study, the result showed that STF-083010 evidently inhibited the upregulation of hepatic α-SMA, Col1α1 and Col1α2 in mice, but these also may be attributed to HSCs expression and the fact that STF-083010 alleviates liver injury by inhibiting CCl~4~-mediated hepatocyte death. Additionally, the study found that CCl~4~-upregulated the mRNA levels of hepatic MCP1, IL-1β, IL-6, and TGF-β1 were attenuated by STF-083010. These results probably suggest that STF-083010 regulates collagen production or degradation (Mmp9) by inhibiting subsequent inflammatory response.

MiRNAs are short (21--24 nucleotides), noncoding RNA molecules that interfere with gene expression at the posttranscriptional level by inducing mRNA degradation or blocking gene translation, which, in turn, decreases or prevents protein synthesis ([@B2]; [@B36]; [@B44]). It was reported that IRE1α was capable of degrading miRNAs, in addition to its well-known capability to degrade mRNA, which provided a new probable connection between IRE1α and miRNAs ([@B54]; [@B18]). MiRNAs had been shown to play an important regulatory role in the pathogenesis and treatment of progressive liver injury including NAFLD and liver fibrosis ([@B33]; [@B38]; [@B50]). Importantly, miR-122 was the high specificity expression accounted for more than 70% of total miRNAs in the adult liver, and a central player in liver biology and disease, which become attractive therapeutic targets ([@B12]; [@B17]; [@B40]). The function of miR-122 was hepatic development, differentiation, homeostasis and metabolism, and was closely related to important liver diseases, such as lipid metabolism, acute liver injury, cirrhosis and HCC ([@B10]; [@B57]; [@B27]; [@B1]; [@B32]). Numerous studies demonstrated that hepatic miR-122 expression was significantly decreased in liver disease and correlated with the degree of liver damage ([@B53]; [@B52]; [@B9]). Recently, a research group investigated that miR-122 negatively correlated with liver fibrosis as detected by histology and FibroScan ([@B13]). Additionally, miR-122 regulated collagen production via targeting HSCs and suppressing prolyl-4-hydroxylase alpha polypeptide I (P4HA1) expression ([@B34]). Indeed, the present study determined that repeated CCl~4~ administration led to obvious downregulation of hepatic miR-122 in mice, and the effect was markedly reversed by STF-083010. This result was probably due to the significant inhibition of IRE1α RNase activity by STF-083010, which prevented it from cleavage by miR-122. However, its specific mechanism will be further explored. In addition, the study demonstrated that the downstream target genes of miR-122, such as Col1α1, Col1α2, CTGF, P4HA1, and Mmp9 mRNAs, were negatively correlated with the expression level of miR-122 in mouse liver. These may be due to STF-083010 alleviates CCl~4~-induced liver damage and inflammation. This study may reveal a new mechanism by which IRE1α RNase controls liver injury and subsequent liver fibrosis associated with hepatic miR-122 and its target genes, but it still needs to be confirmed further.

ER stress and oxidative stress are interacted states that can occur in cells as part of normal physiology ([@B3]; [@B6]). The results of this study found that the expression level of 3-NT (a marker of oxidative stress) was evidently increased in CCl~4~ model group, and IRE1α RNase inhibitor STF-083010 can slightly reduce oxidative stress (please refer to Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}). However, its specific mechanism remains to be further explored. Notably, study has reported that IRE1α RNase specific inhibitor 4μ8C is also a potent cellular antioxidant ([@B5]). Accordingly, the chemical small molecule STF-083010 may also have potential antioxidant effects, which will be further explored in subsequent studies.

On the other hand, to investigate the effect of STF-083010 on mitochondria-associated proteins, we briefly examined the expression levels of mitochondrial heat shock proteins HSPA9 (also known as GRP75, PBP74), HSPD1 and mitochondrial membrane proteins (mitofusin-1/-2, MFN1, and MFN2). These proteins play essential roles in the control of cell proliferation, facilitate the correct folding and assembly of imported proteins and mediate mitochondrial outer membrane fusion ([@B22]; [@B4]; [@B60]). In the present study, the result showed that hepatic HSPA9 and HSPD1 mRNAs were significantly upregulated in CCl~4~-treated mice, but STF-083010 had no effect on their expression. Additionally, long-term CCl~4~ treatment did not significantly affect the expression levels of hepatic MFN1 and MFN2 mRNAs (please refer to Supplementary Figure [S2](#SM1){ref-type="supplementary-material"}). The specific mechanism will be further explored.

The present study found that STF-083010 inhibited CCl~4~-induced liver injury and thus also liver fibrosis in mice. Namely, subsequent observed results were due to the hepatoprotective effect of STF-083010. The results also demonstrated that IRE1α RNase was a potential target of therapy and STF-083010 might be an effective pharmacological agent of chemical therapy in liver fibrosis. However, this study has several limitations. Firstly, the study did not prove the effects of STF-083010 on other models of liver fibrosis. Secondly, the present study did not determine the exact mechanism of IRE1α RNase cleave miR-122. Thirdly, it should be further explored how miR-122 produced in hepatocyte mediated its target gene involved in liver fibrogenesis in HSCs. Additionally, further studies need to define a dose response curve to evaluate the effects of different doses STF-083010 on liver fibrosis.

In summary, the present study illustrated that STF-083010, an IRE1α RNase specific inhibitor, alleviated CCl~4~-induced liver injury and thus protected against liver fibrosis. Furthermore, the present study found that STF-083010 also had an effect on oxidative stress. Mechanistic exploration found that STF-083010 markedly reversed downregulation of hepatic miR-122 in CCl~4~-induced liver fibrosis. Correspondingly, STF-083010 inhibited CCl~4~-induced upregulation of miR-122 target genes. This study provided partial evidence that hepatic IRE1α RNase was involved in CCl~4~-induced liver fibrosis associated with hepatic miR-122. Thus, this study illustrated that IRE1α RNase specific inhibitor STF-083010 might be a potential therapy strategy for patients with progressive fibrotic diseases.
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3-NT

:   3-Nitrotyrosine

α-SMA

:   α-smooth muscle actin

Col1α

:   collagen I alpha

CTGF

:   connective tissue growth factor

ER

:   endoplasmic reticulum

HSPA9

:   heat shock protein family A (Hsp70) member 9

HSPD1

:   heat shock protein family D (Hsp60) member 1

IL-1β

:   interleukin-1 beta

IRE1α

:   inositol-requiring enzyme 1 alpha

MCP1

:   monocyte chemoattractant protein-1

MFN-1/-2

:   mitofusin-1/-2

Mmp9

:   matrix metalloproteinase-9

P4HA1

:   prolyl-4-hydroxylase alpha polypeptide I

TGF-β1

:   transforming growth factor beta-1

XBP1s

:   spliced X-box binding protein 1

XBP1t

:   total X-box binding protein 1.
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